Table 3 Detailed prescribed treatments before the receiving of AT-MSCs and at the last F/U visit
Pt. no | Hx of aGVHD | BoS therapies before AT-MSC | allo-HSCT-AT-MSC interval (mo) | Treatment(s) at the last F/U | F/U duration (mo) | CMV infection post-therapy | Status |
|---|---|---|---|---|---|---|---|
1 | No | PDN (20 mg/d), cyclosporine (75 mg/d), MMF (500 mg/d), and 14 ECP sessions | 8 | PDN (10 mg, two times per week), ruxolitinib (5 mg/d), and 8 ECP sessions | 13 | No | Alive |
2 | Grade III skin and GI | PDN (15 mg/d) and tacrolimus (0.5 mg/d) | 18 | Ruxolitinib (2 mg/d), tacrolimus (0.5 mg, two times per week), and 15 ECP sessions | 20 | No | Alive |
3 | Grade II skin | PDN (25 mg/d), tacrolimus (1 mg/d), and MMF (600 mg/d) | 12 | PDN (10 mg/d), MMF (250 mg/d), tacrolimus (0.5 mg/d), and 19 ECP sessions | 19 | No | Alive |
4 | No | PDN (15 mg/d), sirolimus (1 mg/d), and MMF (125 mg/d) | 9 | PDN (12.5 mg/d), ruxolitinib (5 mg/d), and 18 ECP sessions | 19 | No | Alive |